CENTRAL FAX CENTER

DEC 1 0 2008

FAX TRANSMISSION
DATE: December 10, 2008
PTO IDENTIFIER: Application Number 09/423,037 Patent Number
Inventor: Heery et al.
MESSAGE TO: US Patent and Trademark Office
FAX NUMBER: (571) 273-8300
FROM: ROPES & GRAY LLP
David P. Halstead, J.D., Ph.D.
PHONE: (617) 951-7615
Attorney Dkt. #: ASZD-P01-228
PAGES (Including Cover Sheet): 11
CONTENTS: Amendment in Response to Final Office Action (9 pages) Amendment Transmittal (1 page)
If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7615 and send the original transmission to us by return mail at the address below.
This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.
ROPES & GRAY LLP One International Place, Boston, Massachusetts 02110 Telephone: (617) 951-7000 Facsimile: (617) 951-7050

DEC 1 0 2008

AMENDMENT TRANSMITTAL LETTER							Docket No. ASZD-P01-228	
Application No. 09/423,037		Filing Date February 22, 2000			Examiner J. A. Dunston		Art Unit 1636	
Applicant(s): Heery et al.								
Invention: INHIBITORS OF NUCLEAR PROTEIN/NUCLEAR RECERTOR INTERACTION								
TO THE COMMISSIONER FOR PATENTS Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.								
CLAIMS AS AMENDED								
	Claims Remaining After Amendment	Claims Highest Remaining Number After Previously		Rate				
Total Claims	35	- 56 =	0	х	52.00		0.00	
Independent Claims	1	- 3 =	0	x	220.00		0.00	
Multiple Dependent Claims (check if applicable)								
Other fee (please specify):								
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:							0.00	
x Large Entity Small Entity								
X No additiona	l fee is require	d for this amer	ndment.	_				
Please charge Deposit Account No in the amount of \$ A duplicate copy of this sheet is enclosed.								
A check in th	e amount of \$		to cover	the filin	g fee is enclo	sed.		
Payment by	credit card. Fo	m PTO-2038	is attached.					
The Director is hereby authorized to charge and credit Deposit Account No18-1945 as described below. A duplicate copy of this sheet is enclosed.								
x Credit any overpayment.								
Charge any additional filing or application processing fees required under 37 CFR 1,16 and 1.17.								
Dated: December 10, 2008								
David P. Halstead, J.D., Ph.D. Attorney/Agent Reg. No.: 44,735								
ROPES & GRAY LLP One International Place Boston, Massachusetts 02110 (617) 951-7615								
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.								
Dated: December 10, 2008 Signature: Tone La Horrison)								

RECEIVED
CENTRAL FAX CENTER

DEC 1 0 2008

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: December 10, 2008 Signature:

(Pamela Harrison)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Heery et al.

Application No.: 09/423,037

Filed: February 22, 2000

For: INHIBITORS OF NUCLEAR

PROTEIN/NUCLEAR RECEPTOR

INTERACTION

Docket No.: ASZD-P01-228 (PATENT)

Confirmation No.: 6259

Art Unit: 1636

Examiner: J. A. Dunston

AMENDMENT IN RESPONSE TO FINAL OFFICE ACTION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated October 16, 2008, please amend the above-identified U.S. patent application as follows.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.